The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
Open accessAbstract
During the past decade, a number of large drug trials suggested that the initiation of levodopa therapy should be delayed to reduce the risk of motor complications in patients with Parkinson's disease. However, the relative contribution of the cumulative exposure to levodopa and of disease progression to the pathophysiology of motor fluctuations and dyskinesias is still poorly understood. In this 4-year multicentre study, we investigated a large cohort of patients with Parkinson's disease in a sub-Saharan African country (Ghana), where access to medication is limited and the initiation of levodopa therapy often occurs many years after onset. The primary objective was to investigate whether the occurrence of motor complications is primarily related to the duration of levodopa therapy or to disease-related factors. Study design included a cross-sectional case-control analysis of data collected between December 2008 and November 2012, and a prospective study of patients followed-up for at least 6 months after the initiation of levodopa therapy. Ninety-one patients fulfilled criteria for clinical diagnosis of idiopathic Parkinson's disease (58 males, mean age at onset 60.6 ± 11.3 years). Demographic data were compared to those of 2282 consecutive Italian patients recruited during the same period, whereas nested matched subgroups were used to compare clinical variables. Demographic features, frequency and severity of motor and non-motor symptoms were comparable between the two populations, with the only exception of more frequent tremor-dominant presentation in Ghana. At baseline, the proportion of Ghanaian patients with motor fluctuations and dyskinesias was 56% and 14%, respectively. Although levodopa therapy was introduced later in Ghana (mean disease duration 4.2 ± 2.8 versus 2.4 ± 2.1 years, P < 0.001), disease duration at the occurrence of motor fluctuations and dyskinesias was similar in the two populations. In multivariate analysis, disease duration and levodopa daily dose (mg/kg of body weight) were associated with motor complications, while the disease duration at the initiation of levodopa was not. Prospective follow-up for a mean of 2.6 ± 1.3 years of a subgroup of 21 patients who were drug-naïve at baseline [median disease duration 4.5 (interquartile range, 2.3-5) years] revealed that the median time to development of motor fluctuations and dyskinesias after initiation of levodopa therapy was 6 months. We conclude that motor fluctuations and dyskinesias are not associated with the duration of levodopa therapy, but rather with longer disease duration and higher levodopa daily dose. Hence, the practice to withhold levodopa therapy with the objective of delaying the occurrence of motor complications is not justified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 1×
“Clinical work-up included the UPDRS from part I to part IV (Fahn and Elton, 1987) and Hoehn and Yahr (HY) staging (Hoehn and Yahr, 1967).”
MethodHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Variable expression of Parkinson's disease: A base‐line analysis of the DAT ATOP cohort
Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., et al. (1990) · Neurology · doi:10.1212/wnl.40.10.1529 · Cited by 1,285
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Ballard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Impact of the motor complications of Parkinson's disease on the quality of life
Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005) · Movement Disorders · doi:10.1002/mds.20279 · Cited by 521
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
A clinico-pathological study of subtypes in Parkinson's disease
Selikhova, M., Williams, D. R., Kempster, P. A., Holton, J. L., Revesz, T., & Lees, A. J. (2009) · Brain · doi:10.1093/brain/awp234 · Cited by 461
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Rajput, A. H. (2014) · Movement Disorders · doi:10.1002/mds.25800 · Cited by 290
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Fahn, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.529 · Cited by 245
The natural history of treated Parkinson's disease in an incident, community based cohort
Evans, J. R., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240366 · Cited by 235
Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
Dopamine agonist therapy in early Parkinson's disease
Stowe, R., Ives, N., Clarke, C. E., van Hilten, Ferreira, J., Hawker, R. J., Shah, L., Wheatley, K., & Gray, R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006564.pub2 · Cited by 208
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study
Kempster, P. A., Williams, D. R., Selikhova, M., Holton, J., Revesz, T., & Lees, A. J. (2007) · Brain · doi:10.1093/brain/awm142 · Cited by 191
The clinical progression of Parkinson's disease
Poewe, W. H., & Mahlknecht, P. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70831-4 · Cited by 183
Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson Disease
Hauser, R. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1756 · Cited by 183
Trender-Gerhard, I., Sweeney, M. G., Schwingenschuh, P., Mir, P., Edwards, M. J., Gerhard, A., Polke, J. M., Hanna, M. G., Davis, M. B., Wood, N. W., et al. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.155861 · Cited by 175
Manson, A., Stirpe, P., & Schrag, A. (2012) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2012-120103 · Cited by 167
Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients
Merola, A., Zibetti, M., Angrisano, S., Rizzi, L., Ricchi, V., Artusi, C. A., Lanotte, M., Rizzone, M. G., & Lopiano, L. (2011) · Brain · doi:10.1093/brain/awr121 · Cited by 161
Multi‐center study of Parkinson mortality with early versus later dopa treatment
Diamond, S. G., Marchkham, C. H., Hoehn, M. M. M., MCDOWELL, F. H., & Muenter, M. D. (1987) · Annals of Neurology · doi:10.1002/ana.410220105 · Cited by 150
Protein Intake and Treatment of Parkinson's Disease with Levodopa
Mena, I. F., & Cotzias, G. C. (1975) · New England Journal of Medicine · doi:10.1056/nejm197501232920404 · Cited by 142
Risk factors for levodopa-induced dyskinesias in Parkinson's disease
Grandas, F., Galiano, M. L., & Tabernero, C. (1999) · Journal of Neurology · doi:10.1007/s004150050530 · Cited by 142
Nadjar, A., Gerfen, C. R., & Bézard, E. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.09.013 · Cited by 129
Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia
Carta, M., & Bézard, E. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.070 · Cited by 123
Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel Monkeys
Boyce, S., Rupniak, N. M. J., Steventon, M. J., et al. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199010000-00006 · Cited by 101
Cereda, E., Barichella, M., Pedrolli, C., & Pezzoli, G. (2010) · Movement Disorders · doi:10.1002/mds.23226 · Cited by 101
Self-citationBody Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease
Zappia, M., Crescibene, L., Arabia, G., Nicoletti, G., Bagalà, A., Bastone, L., Caracciolo, M., Bonavita, S., Costanzo, A. D., Scornaienchi, M., et al. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200203000-00004 · Cited by 91
Considerations in the management of parkinsonism
Fahn, S., & Calne, D. B. (1978) · Neurology · doi:10.1212/wnl.28.1.5 · Cited by 88
Guigoni, C., Doveró, S., Aubert, I., Li, Q., Bioulac, B. H., Bloch, B., Gurevich, E. V., Gross, C. E., & Bézard, E. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04196.x · Cited by 82
Levodopa‐induced dyskinesias in tyrosine hydroxylase deficiency
Pons, R. M., Syrengelas, D., Youroukos, S., Orfanou, I., Dinopoulos, A., Cormand, B., Ormazábal, A., Garzía‐Cazorla, A., Serrano, M., & Artuch, R. (2013) · Movement Disorders · doi:10.1002/mds.25382 · Cited by 79
Impact of pramipexole on the onset of levodopa‐related dyskinesias
Constantinescu, R., Romer, M. M., McDermott, M., Kamp, C., & Kieburtz, K. (2007) · Movement Disorders · doi:10.1002/mds.21292 · Cited by 74
Sharma, J. C., Ross, I. N., Rascol, O., & Brooks, D. J. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02106.x · Cited by 74
“Levodopa phobia”: A new iatrogenic cause of disability in Parkinson disease
Kurlan, R. (2005) · Neurology · doi:10.1212/01.wnl.0000152880.77812.5b · Cited by 69
A new look at levodopa based on the ELLDOPA study.
Fahn, S. (2006) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-211-45295-0_63 · Cited by 63
Levodopa in the Treatment of Parkinsonism
Cotzias, G. C. (1971) · JAMA · doi:10.1001/jama.1971.03190260019005 · Cited by 54
Resting Tremor in Parkinson Disease: A Negative Predictor of Levodopa-Induced Dyskinesia
Kipfer, S., Stephan, M. A., Schüpbach, W. M. M., Ballinari, P., & Kaelin‐Lang, A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.147 · Cited by 49
The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia
Zhang, Y., Tang, B., Song, C.-Y., Xu, Q., Lou, M.-X., Liu, Z., Yu, R., Yan, X., & Guo, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.10.018 · Cited by 40
Williams, A. C. (1984) · BMJ · doi:10.1136/bmj.289.6456.1401 · Cited by 32
Linazasoro, G., Blercom, N. V., Bergaretxe, A. G., Manchola, I. F., Laborda, E., & Ruíz-Ortega, J. Á. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181b52792 · Cited by 29
Screening LRRK2 gene mutations in patients with Parkinson’s disease in Ghana
Cilia, R., Sironi, F. M., Akpalu, A. K., Cham, M., Sarfo, F. S., Brambilla, T., Bonetti, A., Amboni, M., Goldwurm, S., & Pezzoli, G. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6210-y · Cited by 27
Self-citationDotchin, C. L., Jusabani, A., & Walker, R. W. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5988-y · Cited by 24
Parkinson’s Disease in sub-Saharan Africa: step-by-step Into the Challenge
Cilia, R., Akpalu, A. K., Cham, M., Bonetti, A., Amboni, M., Faceli, E., & Pezzoli, G. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.28 · Cited by 15
Self-citationTherapeutic strategies to prevent motor complications in Parkinson’s disease
Kieburtz, K. D. (2008) · Journal of Neurology · doi:10.1007/s00415-008-4007-4 · Cited by 14
Tsironis, C. N., Μαρσέλος, Μ., Evangelou, A. M., & Konitsiotis, S. (2008) · Movement Disorders · doi:10.1002/mds.21630 · Cited by 12
Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration
Bézard, E., Olanow, C. W., & Obeso, J. A. (2013) · Movement Disorders · doi:10.1002/mds.25533 · Cited by 6
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Reich, S. G., & Savitt, J. M. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.014 · Cited by 483
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
LeWitt, P. A. (2015) · Movement Disorders · doi:10.1002/mds.26082 · Cited by 391
Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson's Disease · doi:10.1155/2016/9832839 · Cited by 369
Metadata
- Authors
- Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., & Pezzoli, G.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-17
- Volume
- 137
- Issue
- 10
- Pages
- 2731-2742
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2023819204
- Cited by
- 339
- References
- 60
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.